Cargando…

Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study

Background: To test paliperidone extended-release (ER) for efficacy in decreasing methamphetamine (METH) use and reducing psychotic symptoms in METH-dependent patients after detoxification. Rates of adverse events with paliperidone ER versus placebo were also compared. Methods: After discharge and 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gang, Ma, Li, Liu, Xuebing, Yang, Xue, Zhang, Sheng, Yang, Yongde, Xu, Zaifeng, Hao, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761268/
https://www.ncbi.nlm.nih.gov/pubmed/31607961
http://dx.doi.org/10.3389/fpsyt.2019.00656
_version_ 1783453992633761792
author Wang, Gang
Ma, Li
Liu, Xuebing
Yang, Xue
Zhang, Sheng
Yang, Yongde
Xu, Zaifeng
Hao, Wei
author_facet Wang, Gang
Ma, Li
Liu, Xuebing
Yang, Xue
Zhang, Sheng
Yang, Yongde
Xu, Zaifeng
Hao, Wei
author_sort Wang, Gang
collection PubMed
description Background: To test paliperidone extended-release (ER) for efficacy in decreasing methamphetamine (METH) use and reducing psychotic symptoms in METH-dependent patients after detoxification. Rates of adverse events with paliperidone ER versus placebo were also compared. Methods: After discharge and 7 days without medication, 80 treatment-seeking METH-dependent participants were randomly assigned to paliperidone ER (3 mg once daily; n = 40) or placebo (once daily; n = 40) for 84 days under double-blind conditions. The participants attended clinics weekly to provide urine samples that were analyzed for METH metabolites, to complete research assessments, and to receive substance use and medication counseling. Results: Fifty-six percent of follow-up visits and final visits were completed. The placebo group had a significantly lower retention [51.5 days; 95% confidence interval (CI), 41.6–61.4] than the paliperidone ER group (69.4 days,; 95% CI, 61.9–76.9; p = 0.016). Paliperidone ER was a protective factor against psychotic symptom relapse [hazard ratio (HR) = 0.15, p = 0.003]. Moreover, there were statistically significant effects of paliperidone ER on psychosis severity and METH craving, assessed by mean changes in Positive and Negative Syndrome Scale (PANSS) total scores, Clinical Global Impression—Severity (CGI-S) scores, and METH craving scores over time (p = 0.006, p = 0.002, and p = 0.03 for the medication-by-time interaction effect, respectively). There were no statistically significant differences between the two groups in METH use. There were no serious adverse events related to the study drug. Conclusion: Compared with placebo, paliperidone ER administration resulted in a better retention rate and lower psychotic symptom relapse, but we did not find significantly reduced METH use among adults after acute METH detoxification treatment.
format Online
Article
Text
id pubmed-6761268
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67612682019-10-13 Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study Wang, Gang Ma, Li Liu, Xuebing Yang, Xue Zhang, Sheng Yang, Yongde Xu, Zaifeng Hao, Wei Front Psychiatry Psychiatry Background: To test paliperidone extended-release (ER) for efficacy in decreasing methamphetamine (METH) use and reducing psychotic symptoms in METH-dependent patients after detoxification. Rates of adverse events with paliperidone ER versus placebo were also compared. Methods: After discharge and 7 days without medication, 80 treatment-seeking METH-dependent participants were randomly assigned to paliperidone ER (3 mg once daily; n = 40) or placebo (once daily; n = 40) for 84 days under double-blind conditions. The participants attended clinics weekly to provide urine samples that were analyzed for METH metabolites, to complete research assessments, and to receive substance use and medication counseling. Results: Fifty-six percent of follow-up visits and final visits were completed. The placebo group had a significantly lower retention [51.5 days; 95% confidence interval (CI), 41.6–61.4] than the paliperidone ER group (69.4 days,; 95% CI, 61.9–76.9; p = 0.016). Paliperidone ER was a protective factor against psychotic symptom relapse [hazard ratio (HR) = 0.15, p = 0.003]. Moreover, there were statistically significant effects of paliperidone ER on psychosis severity and METH craving, assessed by mean changes in Positive and Negative Syndrome Scale (PANSS) total scores, Clinical Global Impression—Severity (CGI-S) scores, and METH craving scores over time (p = 0.006, p = 0.002, and p = 0.03 for the medication-by-time interaction effect, respectively). There were no statistically significant differences between the two groups in METH use. There were no serious adverse events related to the study drug. Conclusion: Compared with placebo, paliperidone ER administration resulted in a better retention rate and lower psychotic symptom relapse, but we did not find significantly reduced METH use among adults after acute METH detoxification treatment. Frontiers Media S.A. 2019-09-19 /pmc/articles/PMC6761268/ /pubmed/31607961 http://dx.doi.org/10.3389/fpsyt.2019.00656 Text en Copyright © 2019 Wang, Ma, Liu, Yang, Zhang, Yang, Xu and Hao http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Wang, Gang
Ma, Li
Liu, Xuebing
Yang, Xue
Zhang, Sheng
Yang, Yongde
Xu, Zaifeng
Hao, Wei
Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study
title Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study
title_full Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study
title_fullStr Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study
title_full_unstemmed Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study
title_short Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study
title_sort paliperidone extended-release tablets for the treatment of methamphetamine use disorder in chinese patients after acute treatment: a randomized, double-blind, placebo-controlled exploratory study
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761268/
https://www.ncbi.nlm.nih.gov/pubmed/31607961
http://dx.doi.org/10.3389/fpsyt.2019.00656
work_keys_str_mv AT wanggang paliperidoneextendedreleasetabletsforthetreatmentofmethamphetamineusedisorderinchinesepatientsafteracutetreatmentarandomizeddoubleblindplacebocontrolledexploratorystudy
AT mali paliperidoneextendedreleasetabletsforthetreatmentofmethamphetamineusedisorderinchinesepatientsafteracutetreatmentarandomizeddoubleblindplacebocontrolledexploratorystudy
AT liuxuebing paliperidoneextendedreleasetabletsforthetreatmentofmethamphetamineusedisorderinchinesepatientsafteracutetreatmentarandomizeddoubleblindplacebocontrolledexploratorystudy
AT yangxue paliperidoneextendedreleasetabletsforthetreatmentofmethamphetamineusedisorderinchinesepatientsafteracutetreatmentarandomizeddoubleblindplacebocontrolledexploratorystudy
AT zhangsheng paliperidoneextendedreleasetabletsforthetreatmentofmethamphetamineusedisorderinchinesepatientsafteracutetreatmentarandomizeddoubleblindplacebocontrolledexploratorystudy
AT yangyongde paliperidoneextendedreleasetabletsforthetreatmentofmethamphetamineusedisorderinchinesepatientsafteracutetreatmentarandomizeddoubleblindplacebocontrolledexploratorystudy
AT xuzaifeng paliperidoneextendedreleasetabletsforthetreatmentofmethamphetamineusedisorderinchinesepatientsafteracutetreatmentarandomizeddoubleblindplacebocontrolledexploratorystudy
AT haowei paliperidoneextendedreleasetabletsforthetreatmentofmethamphetamineusedisorderinchinesepatientsafteracutetreatmentarandomizeddoubleblindplacebocontrolledexploratorystudy